The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine Kinase

NCT02755337 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2016-04-28

No results posted yet for this study

Summary

To evaluate Non-Small Cell Lung Cancer (NSCLC) patients clinical profile and the outcome after treatment with Gefitinib in Pulmonary Oncology Outpatient Clinic Dr. Soetomo General Hospital, Surabaya, Indonesia.

Conditions

  • Non-Small-Cell Lung Cancer

Sponsors & Collaborators

  • Dr. Soetomo General Hospital

    lead OTHER_GOV

Principal Investigators

  • Laksmi Wulandari, MD, PhD · Dr. Soetomo General Hospital

Eligibility

Min Age
16 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-07-31
Completion
2016-12-31

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02755337 on ClinicalTrials.gov